Astinova Blog

Chemistry, Drug Discovery, and Advanced Modalities

Working notes from the Astinova chemistry team — synthesis case studies, modality deep dives, and observations from real drug discovery programs.

medicinal chemistry· · 4 min read

(S)-(+)-14: A Brain-Penetrant Covalent Butyrylcholinesterase Inhibitor with In Vivo Procognitive Efficacy — Target & Lead Intelligence Dossier

A structure-guided, brain-penetrant covalent BChE inhibitor for late-stage Alzheimer's: (S)-(+)-14 carbamoylates the catalytic Ser198 (hBChE IC50 30 nM, no AChE activity), is CNS+, and reverses scopolamine-induced cognitive deficits in mice with no cholinergic side effects — with a co-crystal to prove the mechanism.

Read article →
medicinal chemistry· · 4 min read

Triple Combination Therapy Against β-Lactamase-Mediated Resistance: β-Lactam + SBL Inhibitor + MBL Agent — Target & Strategy Intelligence Dossier

Why no single inhibitor fixes β-lactamase-mediated AMR — and how triple combination therapy (β-lactam + SBL inhibitor + MBL-targeting agent) bridges the gap. The inhibitor landscape, the serine vs di-zinc mechanisms, and the FDA-approved aztreonam–avibactam (Emblaveo) milestone, with original structures and binding renders.

Read article →